StockNews.AI
REPL
StockNews.AI
11 days

Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025 - REPL

1. Replimune Group faces a class action securities lawsuit. 2. The lawsuit targets alleged securities fraud from November 2024 to July 2025. 3. Claims include false statements about IGNYTE trial's prospects. 4. Investors can participate without cost until September 22, 2025. 5. Levi & Korsinsky represents the class, focusing on securities litigation.

8m saved
Insight
Article

FAQ

Why Bearish?

Class action lawsuits often lead to a loss of investor confidence, negatively impacting stock prices. Historical examples include cases where similar fraud allegations caused stocks to decline significantly.

How important is it?

The lawsuit significantly impacts REPL's credibility, exposing potential vulnerabilities in future operations and investor sentiment.

Why Short Term?

The immediate concern from the lawsuit could trigger a quick sell-off in REPL shares. Previous similar cases have shown that stock price reactions often occur within weeks after lawsuit announcements.

Related Companies

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ:REPL) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=160203&wire=4

REPL investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

WHAT'S NEXT? If you suffered a loss in Replimune Group, Inc. during the relevant time frame, you have until September 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 17th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-replimune-group-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-september-22-2025--repl-302524913.html

SOURCE Levi & Korsinsky, LLP

Related News